What role does stereotactic ablative radiotherapy have in advanced castrate-resistant prostate cancer?

about

What role does stereotactic ablative radiotherapy have in advanced castrate-resistant prostate cancer?

Item

http://www.wikidata.org/entity/Q47904167

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

What role does stereotactic ab ...... ate-resistant prostate cancer?

@en

What role does stereotactic ab ...... ate-resistant prostate cancer?

@nl

type

Item

label

What role does stereotactic ab ...... ate-resistant prostate cancer?

@en

What role does stereotactic ab ...... ate-resistant prostate cancer?

@nl

prefLabel

What role does stereotactic ab ...... ate-resistant prostate cancer?

@en

What role does stereotactic ab ...... ate-resistant prostate cancer?

@nl

P1476

What role does stereotactic ab ...... ate-resistant prostate cancer?

@en

P2093

Piet Ost

http://www.w3.org/2001/XMLSchema#string

Ryan Phillips

http://www.w3.org/2001/XMLSchema#string

P2860

10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer

PET imaging of prostate-specific membrane antigen in prostate cancer: current state of the art and future challenges

Androgen receptor signaling in castration-resistant prostate cancer: a lesson in persistence

A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE)

Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence

Stereotactic radiation therapy can safely and durably control sites of extra-central nervous system oligoprogressive disease in anaplastic lymphoma kinase-positive lung cancer patients receiving crizotinib.

Surveillance or metastasis-directed Therapy for OligoMetastatic Prostate cancer recurrence (STOMP): study protocol for a randomized phase II trial

Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019).

Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer.

The evolutionary history of lethal metastatic prostate cancer.

P304

2121-2124

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.2217/FON-2017-0337

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Phuoc T. Tran

P577

2017-10-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29019420

http://www.w3.org/2001/XMLSchema#string